Development of recombinant adeno-associated virus vector based anti-tumor vaccine

Faculty Mentor

George Aslanidi, PhD
Research Assistant Professor
(352) 273-8257

Research Project Description

My research is focused on production and application of recombinant adeno-associated virus (rAAV) as gene therapy vectors. We use rAAV vectors to regulate therapeutic transgenes expression and retarget such rAAV vectors to provide a more specific and efficient means for gene therapy. Students will participate in developing a novel recombinant AAV vector for the selective and efficient transduction of different subsets of human dendritic cells. Also, evaluate the ability of AAV-based delivery of tumor antigen to dendritic cell to initiate robust cytotoxic-T-cell response for specific killing of tumor cells. Funding for these projects is provided by National Institute of Health.

Jayandharan GR, Aslanidi G, Martino AT, Jahn SC, Perrin GQ, Herzog RW, Srivastava A. Activation of the NF-{kappa}B pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proceedings of the National Academy of Sciences USA, 108(9): 3743-3748, 2011.

Aslanidi G, Lamb K, Zolotukhin S. An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proceedings of the National Academy of Sciences USA, 106(13):5059-64, 2009.